Sushmita Panda - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Sushmita Panda's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Sushmita Panda
Verified
Pharma Reporter, Citeline
New Delhi, Delhi
Beats
Biography
Sushmita Panda is a New Delhi-based journalist with over six years of experience covering the healthcare and pharmaceutical sectors. She has reported on critical issues including drug patents and discovery, rare diseases, innovative therapies, women’s health, Neglected Tropical Diseases (NTDs), mental health, drug access, and regulatory affairs. Over the years, she has authored numerous in-depth stories and on-ground reports on diseases prevalent in India, including several exclusives and interviews with industry leaders. An alumna of the Asian College of Journalism and the University of Delhi, Sushmita has worked with national and international publications such as Financial Express, Sputnik, The Sunday Guardian, and India TV.
BusinessHealth and Social issues. Politics
Entertainment, Lifestyle, and sports.
Content
By Sushmita Panda Verified| Financial Express Verified US President Donald Trump has announced reciprocal tariffs on about 60 countries to counter higher duties imposed globally on American products. Pavan Choudary, Chairman, Medical Technology Association of India (MTaI) said that the U.S. administration’s decision to impose reciprocal tariffs does not reflect informed policymaking. “History has repeatedly shown that protectionist measures often do more harm than good, with the burden ultimately falling on consumers and patients in both countries.
By Sushmita Panda Verified| Financial Express Verified US President Donald Trump has exempted pharmaceuticals from his reciprocal tariff plan announced on April 3. While he imposed a 26% tariff on other imports from India, this exemption has provided significant relief to pharmaceutical companies. However, experts warn that the relief may be short-lived.
By Sushmita Panda Verified| Financial Express Verified Novartis on Thursday announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia (atrasentan) to treat primary immunoglobulin A nephropathy (IgAN), also known as Berger’s disease. Vanrafia is a once-daily, non-steroidal, oral treatment that can be added onto supportive care, including a renin-angiotensin system (RAS) inhibitor with or without a sodium-glucose co-transporter-2 (SGLT2) inhibitor, the company said in a statement.
Company Info
Citeline
New York, New York, United States
+1 646-957-8919